Inherited variability, known as polymorphisms, has been recognized as an important contributor to mouse models of cancer for 100 years. Early studies using outbred populations of mice established that cancer susceptibility was an inherited trait 1 , long before DNA was established as the genetic material. However, it was recognized early on that variability owing to uncontrolled genetic factors segregating in these populations was confounding the ability of researchers to interpret their results. As a result, starting with the pioneering work of C.C. Little and colleagues 2 , investigators began to develop inbred mouse strains to eliminate uncontrolled inherited variability, and this resulted in the dilute brown albino (DBA) strain 2 , which was the first inbred mouse strain. Shortly thereafter, additional strains were developed by L.C. Strong and colleagues 3 . Subsequently, investigators began to use the nascent inbred strains in chemical carcinogenesis and genetic mapping experiments to establish the multigenic nature of cancer susceptibility 4 . As much of this work was carried out before the advent of molecular biology, the co-segregation of phenotypes of interest with visible markers, such as the albino coat colour mutation, was used to map the first cancer susceptibility genes. On the basis of results obtained using these strategies, investigators not only recognized that different genetic backgrounds displayed significantly different susceptibilities to cancers, but they were also able to begin to estimate the number of susceptibility genes and to assign them to linkage groups 5 .
These strategies, which focused on inherited factors of cancer susceptibility, encompassed much of mouse cancer modelling in the first 60-70 years of the twentieth century. With the development of recombinant DNA technology, there was a realization that cancers accumulate somatic mutations of endogenous genes, and the ability to manipulate and to engineer the mouse genome radically changed the way that mouse cancer modelling was approached. Rather than looking at how population dynamics results in changes in cancer incidence, the focus is now on molecular mechanisms and modelling individual mutations. Although genetically engineered mouse (GEM) models (for example, transgenic and knockout models) have been extremely valuable for providing tremendous advances in our understanding of the molecular aetiology of cancer, they have come at a price. Ironically, considering the reason that they were originally generated was to model human cancer development, inbred GEM models represent, at best, single individuals in the human population. Thus, it is difficult to successfully translate information that is garnered from inbred mouse models back into human populations.
Therefore, the purpose of this Opinion article is to re-examine the need to incorporate polymorphism-based population diversity into our analysis of GEM cancer models. Inherited polymorphism can have profound effects on experimental outcome in animal model studies. It is thus important to recognize these potential confounds and to appropriately design experiments to account for any unexpected effects. Inherited polymorphism is not only an experimental problem, but it can also provide valuable insights into biological mechanisms. Incorporating this aspect of biology into the research portfolio of the average cancer research laboratory would thus be an important step towards improving the prognostic value of mouse models.
Problems with polymorphisms
An underappreciated problem with GEM models is the unrecognized re-introduction of polymorphisms into the experimental mix. The standard procedure for generating GEM models is to engineer the desired genetic alterations in embryonic stem cells (ESCs), and then to introduce the engineered alterations into the germ line via chimaera, with transmission monitored by outcrossing to other strains that have different coat colours 6 (FIG. 1) . This strategy can potentially result in animals that have an undefined, mixed genetic background, which will invariably increase genetic variability or may even alter the phenotype of interest. The introduced variability does not necessarily result in subtle phenotypic changes. An example is the rescue of the embryonic lethal epidermal growth factor receptor (Egfr)-null mutation. On a CF-1 outbred background, Egfr-homozygous mutant embryos die around implantation. However, on a 129/Sv inbred strain background embryos survive until mid-gestation, and when on an ALR/LtJ background, Egfr-homozygous mutants survive until birth and can live as long as 3 weeks after birth 7 . Unless undefined segregating polymorphisms are bred out of GEM models, variability will continue to be a confounding problem. Another potential example of this problem was identified by a transgenebased study of the p53 arginine to serine point mutation that is seen in aflatoxinassociated hepatocellular carcinoma (HCC). Analysis of aflatoxin-induced HCC susceptibility in mice expressing the mutant p53 protein in a mixed C57BL/6 and DBA/2J background led to the conclusion that this point mutation enhanced the carcinogenic effect of aflatoxin 8 . What was not considered was that the DBA/2J genome itself is more sensitive than the C57BL/6 genome to aflatoxin-induced carcinogenesis, potentially owing to polymorphic differences in xenobiotic-metabolizing enzymes 9 . Not controlling the background leads to the common mishandling of GEM models. Investigators frequently propagate models that are generated after coat colour transmission testing without repeated backcrossing to an existing inbred strain, which results in Abstract | Mouse models are indispensible tools for understanding the molecular basis of cancer. However, despite the invaluable data provided regarding tumour biology, owing to inbreeding, current mouse models fail to accurately model human populations. Polymorphism is the essential characteristic that makes each of us unique humans, with different disease susceptibility, presentation and progression. Therefore, as we move closer towards designing clinical treatment that is based on an individual's unique biological makeup, it is imperative that we understand how inherited variability influences cancer phenotypes, how it can confound experiments and how it can be exploited to reveal new truths about cancer biology. Ten generations of crossing to black strain the generation of partially inbred strains. For models that can be carried as homozygotes, it is possible to develop a new strain that is a random mix of the original progenitor strains and without an experimental control (FIG. 1) . In this situation, phenotyping all of the littermates provides some level of experimental control. However, as the genotypes of both the experimental and the control littermates are not stable, genotypes and phenotypes can shift over time, preventing unambiguous interpretation between sequential experiments. Novel gene-gene interactions within the derived GEM strain may lead to a different baseline physiology compared with either progenitor strain. This problem could be exacerbated when combining two GEM models with ill-defined backgrounds. Thus, results obtained by comparing GEM models on uncontrolled backgrounds to the progenitors would be ambiguous, as it may not be clear whether the phenotypic variation is due to the genetic background, the engineered genes, polymorphisms in the donor DNA flanking the engineered genes, or a combination of all of these.
To reduce this problem, suppliers such as The Jackson Laboratory backcross GEM models onto a single genetic background. This results in a congenic strain in which a single subchromosomal fragment of a donor strain is substituted for the same interval in a different inbred recipient strain (FIG. 1) . These congenic strains usually contain a segment of the ESC donor genome surrounding the engineered alteration on a C57BL/6J background. Although this greatly reduces the potential confounding effect of background polymorphism, it does not completely eliminate it. Therefore, appropriate care should be exercised in the use and the interpretation of GEM models, particularly when combining different engineered genes by breeding. To properly interpret results, all genotype classes -and in particular, background-matched controls -should be saved and phenotyped to most accurately assess any phenotype variation that may be due to the engineered genes compared with unknown and unanticipated variation that is due to genetic background.
The potential promise of polymorphisms Intriguingly, polymorphisms in GEM models are not just experimental confounds. Genetic variation also represents an opportunity to better understand the complex physiology that is associated with cellular equilibrium and neoplastic transformation. As evidenced by the incomplete penetrance of breast cancer in BRCA1 and BRCA2 mutation carriers 10 , polymorphic variants in other genes can have major effects on tumour incidence and biology even in patients with constitutional mutations in important tumour suppressor genes. Deep-sequencing technologies are currently identifying many somatically altered cancer driver genes. The identification and characterization of inherited cancer modifier genes may, therefore, be a valuable complement, providing important information regarding how cells and organisms have evolved to try to prevent cancers. Even if polymorphic genes themselves are not identified, exploring the construction of biological networks that are based on inherited, rather than somatic, diversity can provide important information regarding molecular and cellular processes that are associated with disease initiation and progression 11 . Furthermore, Germline transmission of the engineered chromosome (represented by vertical rectangles) is achieved by breeding the chimeric founder with a mouse that has a different coat colour. The proportions of the genome from the ESC donor strain and the recipient strains are depicted by the circles below the chromosome rectangles. Because albinism is recessive, the F1 progeny is crossed back to an albino mouse. The occurrence of albino mice in the second generation (F2) indicates successful germline transmission of the ESC genome (shown in the dashed box). Note that the coat colour mutation is not usually linked to the engineered locus and, therefore, the coat colour mutation will segregate independently in the progeny. These mice will not only carry the engineered locus (indicated by the asterisk) but also 25% of the black genome. Repeated crossing of the engineered locus back to the black mouse strain results in a congenic animal that is homozygous black for the entire genome except the region surrounding the locus of interest. Repeated brother-sister mating to carry the construct of interest homozygously, without first generating congenics, can result in novel inbred (recombinant congenic) strains that are composites of the ESC donor and the recipient genomes.
as cancer-modifying genetic networks may affect mechanisms that are not directly associated with driver mutations, these networks might be more amenable to pharmacological manipulation than the permanently mutated oncogenic genes.
The shift in mouse modelling from inherited to somatic genetics is easy to understand, as it has been primarily driven by changes in technology. The rapid evolution of strategies for identifying somatically altered genes has far outpaced our ability to identify naturally occurring variants that modify phenotypes of interest. For example, the ability of massively parallel high-throughput sequencing to identify potential cancer driver mutations is limited primarily by the acquisition of sufficiently high-quality samples for analysis. Similarly, improvements in genetic mapping capabilities and technologies have resulted in the detection of hundreds of modifier or susceptibility loci in both mice (Mouse Genome Informatics; see Further information) (BOX 1) and humans [12] [13] [14] . The difficulty has not been identifying the presence of these modifier loci, but rather identifying and validating exactly which genes are responsible for modulating the phenotype of interest. Unlike tumour suppressors and oncogenes that have a basically digital phenotype -that is, tumour or no tumour -polymorphic genes have an analogue output. Thus, there are considerably more barriers to the identification and validation of these genetic factors than there are for somatically altered genes.
Despite these challenges considerable progress has been made towards identifying low-penetrance modifier genes. Polymorphic genes that affect phenotypes (modifiers) have been identified in a number of mouse models of neoplasia. The first modifier identified was in the Apc min model of dominant familial adenomatous polyposis. The modifier, known as modifier of Min1 (Mom1), was first detected by a reduction of intestinal adenomas when the C57BL/6-based Apc min animal was bred with either AKR/J or MA/MyJ inbred strains 15 .
Subsequent studies demonstrated that the modifier was a polymorphism in the gene that encodes secretory type II phospholipase A2 (PLA2G2A) 16 . Modifiers have also been identified from chemical carcinogenesis screens. Investigators have taken advantage of the inherent differences in carcinogen sensitivity of different mouse strains and subspecies to map and to subsequently clone a polymorphic variant of the aurora kinase A (AURKA) gene that functions as a cancer susceptibility gene in both mice and humans 17 . The incorporation of GEM models in polymorphism screens permits the investigation of particular pathways or processing by using mouse strains selected for or engineered to express a phenotype of interest. For example, genes and loci have been identified that modify the latency 5, 6 , growth 7 and metastatic progression 18 of transgene-induced tumours. Similarly, modifier loci have been identified using genetic engineering technologies to model the effects of inherited polymorphism on tumour suppressor biology 19 . Epidemiology studies for some of the low-penetrance mouse susceptibility genes suggest similar roles in human disease 17, 20, 21 . The GEM models have several attractive features for use in screens for inherited variants that modify phenotypes of interest. First, they represent specific mutational events and tumour subtypes. Second, screens can be carried out in controlled environments to reduce the experimental 'noise' that cannot be controlled or even fully described in human populations. Third, the screens are fairly rapid, owing to the short lifespan of the mouse. Fourth, susceptibility loci can be identified with relatively small sample sizes compared with large multi-institution, genome-wide association studies in humans because the lineage and breeding history of the population is known. In addition, because the breeding structure and the environment of the experimental subjects can be controlled, mouse genetic screens usually require many fewer individuals than human studies to achieve significant results. Last, unlike epidemiology studies, it is possible to directly validate any gene in the mouse by generating new GEM models to test the role of specific genes in the phenotype of interest.
Exploiting polymorphisms
To fully exploit the potential of inherited polymorphism it is necessary to rapidly and efficiently identify the variant genes of interest. As alluded to above, a number of strategies have been developed to achieve this goal (see, for example, . Owing to space limitations the intent of this article is not to comprehensively review the relative strengths and weaknesses of these approaches. Instead the focus is on a fairly new resource that can be adapted for use by the non-geneticist not only for carrying out population studies on their favourite mouse models, but also for easily integrating their results with independent studies from other laboratories.
One way to rapidly and efficiently identify variant genes of interest would be for individual investigators to carry out the population analysis and genetic mapping using a common genetic mapping resource, based on a recombinant inbred (RI) panel. RI panels are developed from intercrosses of established strains 25 (FIG. 2a) . F1 progeny from progenitor strains are then bred by strict brother-sister mating for 20 or more generations to yield new sublines that are genetic mixes of the original parents 25 .
Box 1 | Useful online resources for mouse genetics and cancer modelling
• The Origins of Inbred Mice 3 is available online from the Mouse Genome Informatics (MGI) website (see Further information). This website is maintained by The Jackson Laboratory and integrates access to several databases providing genetic, genomic and biological data on the laboratory mouse to aid its use as a model of human diseases.
• The Mouse Tumor Biology Database is part of the MGI database. It integrates data on tumour frequency, incidence, genetics and pathology in mice to support the use of the mouse as a cancer model. • The Mouse Phenome Database is also maintained by The Jackson Laboratory and contains strain characterization data (phenotype and genotype) for the laboratory mouse, to facilitate translational research.
• The electronic Models Information, Communication, and Education (eMICE) database is maintained by the US National Cancer Institute and provides information about a wide variety of animal models of cancer, including mice. If sufficient numbers of sublines are generated, inherited traits that differ between the progenitor strains can be readily mapped by screening the trait across the sublines and comparing the phenotype to the segregation of the parental genomes. Importantly, as the sublines are inbred, genotyping only needs to be carried out once. Subsequently, all additional traits can be mapped by simply using the pre-existing genetic mapping information. Furthermore, multiple animals with the identical genotype can be screened. For phenotypes with substantial variation owing to random or uncontrollable factors, the ability to phenotype multiple animals of the same genotype enables a more precise measurement of the influence of genotype versus random fluctuation on a complex trait, which improves genetic mapping and resolution. Moreover, as the RI panels are inbred, they represent a stable source of identical segregating genotypes.
In standard genetic mapping panels that are based on intercross or backcross strategies, each animal is genetically unique and can, therefore, only be used to study a single phenotype. By contrast, RI panels, which are based on panels of inbred strains, are an infinite source of identical animals that segregate different segments of the original donor genomes. This feature permits, in at least some instances, the opportunity for multiple investigators with similar experimental designs to assay and to integrate the genetic screens on a single genetic mapping panel. Furthermore, the inbred nature of RI lines provides an immortalized, almost unlimited, tissue resource, which facilitates the incorporation of new analyses with historical data as novel technologies are developed. These advantages were the basis for the recent development of a novel RI panel that is known as the Collaborative Cross (CC) 26 (see the Collaborative Cross Status website; see Further information) (BOX 1; FIG. 2b) . The CC reference panel was built on this foundation as an easy-to-use population genetics tool. To better model the diversity that is observed in humans, the CC is being generated from eight progenitor mouse strains, including three wild-derived strains. A randomized breeding scheme and a goal to generate a panel of hundreds of sublines combined with computational strategies to identify segregating haplotypes will theoretically permit mapping down to the megabase level. This level of resolution, combined with whole-genome sequencing of the eight progenitor strains and other systems biology tools, will enable the rapid identification of candidate genes for validation. Thus, in many ways, the CC RI panel was designed to reduce much of the tedious and expensive steps to achieve high-resolution mapping by conventional backcross or intercross analysis, in a format that can be easily used by investigators without extensive experience in meiotic genetics.
Use of this resource would be fairly simple. For cancer models with a dominant phenotype, such as transgenic models and some knockout models, investigators would examine population diversity by simply generating F1 progeny between their models and some or all of the CC lines (FIG. 3a) . As 50% of the chromosomes from the F1 cross will be from the GEM model, any loci that would modify the normal GEM model phenotype would have to be attributed to DNA from the RI strain. Thus, the identification of modifier loci can be carried out by comparing the phenotypes of all of the outcrosses from GEM models crossed with RI sublines with the previously known RI genotypes. In our hands, using one of the original RI panels 27 , this strategy has substantially contributed to the identification of metastasisrelated susceptibility genes 18, 28 , and has also been the basis for further systems genetic analyses 20, 29, 30 . For GEM models that require homozygosity to generate a cancer phenotype the situation is somewhat more complex. The investigators would need to generate F1 hybrids with multiple CC lines and then intercross the F1 progeny or backcross them with the GEM parental line. The resulting intercross F2 or backcross N2 progeny would display a new distribution of the phenotype for each GEM-CC subline combination owing to the segregation of the CC genome. The median phenotype value from each GEM-CC subline cross (FIG. 3b) for mapping using the known CC parental genotypes to identify loci that alter the median phenotype across the CC panel (FIG. 3c) . Additional complementary linkage information could also be obtained by carrying out high-density genotyping of interesting GEM-CC subline combinations to map individual modifiers that are present within a particular GEM-CC pair (FIG. 3c) .
The costs of understanding how underlying polymorphism may be affecting the interpretation of GEM experiments for the average investigator would, therefore, be limited to animal breeding and housing costs. Although these are not insubstantial expenses, information gleaned from these experiments may re-direct time, effort and resources towards avenues of research that are more representative of the human population rather than towards experimental systems that represent only a small proportion of the human cancer population. Furthermore, elucidating the variability in cancer that is encoded by inherited polymorphism may reveal unexpected insights and interconnections that could be clinically exploited to prevent or to treat neoplastic disease.
Conclusions
In summary, as the cancer research and oncology communities continue towards treatment that is based on an individual's unique characteristics, all the factors that influence tumour biology must be considered. Technology and computational capabilities have advanced to the point where systems-wide interactions can be constructed and examined. Our mouse models of cancer need to fully embrace this complexity by the reintroduction of population diversity into cancer modelling rather than relying on single variable systems that are based on inbred strains. Incorporating the effect of inherited polymorphism with that of somatic mutation should not only better inform us of who is susceptible to cancer, but should also aid, for example, in identifying patients who are susceptible to specific drug toxicities, which therapies may be most effective in a given individual and which individuals have tumours that are most likely to progress. Just as polymorphism makes each of us unique individuals, being aware of, and exploiting, population diversity will improve our ability to more accurately model cancer in animal systems to improve cancer outcomes. b | A mating strategy for recessive GEM models is shown. The GEM model is bred with CC lines to generate F1 animals, which are then intercrossed (left) or backcrossed (right) with the GEM model to produce homozygous knockout models. Owing to the segregation of the CC genome in these animals, a small population is phenotyped to generate a median phenotype value for that population, which is based on both the segregating background and the engineered locus for each CC line. c | Genetic mapping for recessive GEM models is shown. Each of the CC-GEM model crosses that are produced would result in a population with a distribution of the phenotype in question. The median phenotypic value of each CC-GEM cross, however, would probably be different depending on the complement of modifiers introduced by each CC line. These median values for each cross can then be used as a meta-phenotype to map modifiers that influenced the median phenotype value by comparison with the CC parental genotypes. No additional genotyping is required for this. Additional linkage information can be obtained by genotyping any of the CC-GEM crosses to further map and/or refine modifiers that are present in any particular CC subline of interest.
